Loading…
Please register to continue your trial period!
meRfi Microbiome provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.
Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.
Start your free trial and transform your understanding of the gut microbiota today!
The FDA approved venetoclax (Venclexta TM) on June 8, 2018, for patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). This approval includes patients with or without the 17p deletion, provided they have undergone at least one prior therapy. In 2019, the FDA expanded its approval to include untreated adult patients with CLL or SLL, based on the results of the CLL14 study. In this context, [venetoclax is used in combination with obinutuzumab](brain://7FVfNFpcCUmB2vTnw-jCyA/ObinutuzumabVenetoclaxChronicLymphocyticLeukemiaCllSmallLymp…